Skip to main content

Advertisement

Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib

Fig. 4

Co-delivery of sorafenib and metapristone by LFC131-modified NPs enhanced anti-proliferative activity and promoted cell apoptosis. a The in vitro anti-proliferative ability of different formulations in SMMC-7721 cells was determined by MTT assay after 24-h and 48-h incubation. Data are expressed as the mean ± SD (n = 5). *P < 0.05, **P < 0.01, ***P < 0.001. b After 24-h incubation, the effect of different formulations on SMMC-7721 cells colony formation was evaluated by colony formation assay. The data were shown by representative photographs (left panels) and quantitative analysis of colony numbers for each sample (right panels). Data are expressed as the mean ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001. c After incubation with different formulation for 48 h, the apoptosis was determined by Annexin V-FITC/PI staining and characterized by the proportion of cells in early and late apoptotic phase by flow cytometry analysis. d The western blot analysis showed LFC-Sora/Meta-NPs significantly induced the activation of caspase-3, caspase-9 and PAPR, and increased the expression levels of p-p38, p53 and Bax, concomitant with the reduction in expression levels of CXCR4, Bcl-2, p-Akt and p-ERK, following incubation for 48 h. All experiments were repeated at least three times

Back to article page